Apoxis Acquires Worldwide Rights for Novel Anti-Cancer Compound from Astellas Pharma
Under the terms of the agreement, Apoxis receives a worldwide exclusive license. In return, Apoxis will make an upfront payment and a series of milestone payments based on successful development and approval of APO866. Apoxis will also make royalty payments based on net sales. No further terms were disclosed.
APO866 is a first-in-class cancer drug with a novel mechanism of action that selectively depletes a cancer cell's energy, leading to apoptotic death in cancer cells, and exerts anti-angiogenic activity. A phase I study in the US and Germany established that the drug was safe and well-tolerated in patients with advanced cancer. This, combined with preclinical efficacy results, provides a strong platform for further development of APO866. Apoxis intends to initiate three phase II clinical studies in 2006.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.